S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
S&P 500   3,934.38 (-0.73%)
DOW   33,476.46 (-0.90%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:GMDA

Gamida Cell - GMDA Stock Forecast, Price & News

$1.28
-0.01 (-0.78%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.23
▼
$1.29
50-Day Range
$1.29
▼
$2.10
52-Week Range
$1.23
▼
$4.72
Volume
466,471 shs
Average Volume
677,841 shs
Market Capitalization
$75.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Gamida Cell MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
900.0% Upside
$12.80 Price Target
Short Interest
Bearish
6.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Gamida Cell in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$39,999 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.18) to ($0.99) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

784th out of 1,022 stocks

Biological Products, Except Diagnostic Industry

128th out of 171 stocks

See Top Rated MarketRank™ Stocks Here
GMDA stock logo

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

December 9, 2022 | americanbankingnews.com
Head to Head Analysis: Gamida Cell (NASDAQ:GMDA) and Mosaic ImmunoEngineering (OTCMKTS:CPMV)
November 21, 2022 | finance.yahoo.com
Gamida Cell Provides Regulatory Update on Omidubicel
November 14, 2022 | finance.yahoo.com
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
November 10, 2022 | finance.yahoo.com
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
November 7, 2022 | finance.yahoo.com
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
November 7, 2022 | finance.yahoo.com
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
November 3, 2022 | finance.yahoo.com
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
October 10, 2022 | finance.yahoo.com
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
September 29, 2022 | markets.businessinsider.com
Gamida Cell: Omidubicel Follow Up Data Shows 63% Overall Survival At Three Years
September 29, 2022 | finance.yahoo.com
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
September 28, 2022 | marketwatch.com
Gamida Cell Shares Slide Premarket After Public Offering, Financing >GMDA
September 28, 2022 | finance.yahoo.com
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
September 28, 2022 | finance.yahoo.com
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
September 19, 2022 | marketwatch.com
Gamida Cell Names Abigail L. Jenkins as President, CEO
September 19, 2022 | markets.businessinsider.com
Gamida Cell Appoints Abigail Jenkins To Succeed Julian Adams As President And CEO
September 19, 2022 | finance.yahoo.com
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
September 12, 2022 | finance.yahoo.com
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
August 17, 2022 | msn.com
Earnings
August 15, 2022 | fool.com
Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript
August 15, 2022 | seekingalpha.com
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript
August 15, 2022 | finance.yahoo.com
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
August 10, 2022 | finance.yahoo.com
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
August 9, 2022 | finance.yahoo.com
These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer
August 8, 2022 | finance.yahoo.com
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
August 4, 2022 | finance.yahoo.com
How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?
See More Headlines
Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Company Calendar

Last Earnings
11/14/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
CUSIP
N/A
CIK
1600847
Web
www.gamida-cell.com
Phone
(722) 659-5666
Fax
N/A
Employees
166
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.80
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-387.05%
Return on Assets
-70.54%

Debt

Debt-to-Equity Ratio
5.31
Current Ratio
2.76
Quick Ratio
2.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.74 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
59,200,000
Free Float
57,661,000
Market Cap
$75.78 million
Optionable
Not Optionable
Beta
1.58

Key Executives

  • Mr. Shai Lankry CPA (Age 46)
    M.B.A., Chief Financial Officer
    Comp: $564k
  • Ms. Michele Ilene Korfin M.B.A. (Age 50)
    R.Ph., Chief Operating & Chief Commercial Officer
    Comp: $510k
  • Dr. Ronit Simantov M.D. (Age 57)
    Chief Medical & Chief Scientific Officer
    Comp: $581k
  • Dr. Jas Uppal Ph.D. (Age 54)
    Chief Regulatory Officer
    Comp: $476k
  • Ms. Abigail L. Jenkins (Age 46)
    Pres, CEO & Director
  • Mr. Joshua F. Patterson (Age 46)
    Gen. Counsel & Chief Compliance Officer
  • Mr. Paul Nee
    VP of Marketing
  • Mr. Naftali Brikashvili CPA
    Sr. VP Fin. & Operations
  • Dr. Tracey Lodie Ph.D. (Age 52)
    Scientific Advisor & Consultant
  • Mr. Vladimir Melnikov
    Sr. VP of Global Operations & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings or view top-rated stocks.

What is Gamida Cell's stock price forecast for 2023?

5 equities research analysts have issued 12-month price targets for Gamida Cell's stock. Their GMDA share price forecasts range from $7.00 to $22.00. On average, they expect the company's share price to reach $12.80 in the next year. This suggests a possible upside of 907.9% from the stock's current price.
View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2022?

Gamida Cell's stock was trading at $2.54 at the start of the year. Since then, GMDA shares have decreased by 50.0% and is now trading at $1.27.
View the best growth stocks for 2022 here.

When is Gamida Cell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our GMDA earnings forecast.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02.

What other stocks do shareholders of Gamida Cell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by many different institutional and retail investors. Top institutional shareholders include Meitav Dash Investments Ltd. (6.17%), Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD (3.74%), Federated Hermes Inc. (2.60%), Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD (1.35%), BlackRock Inc. (0.78%) and Marshall Wace LLP (0.62%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends.

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $1.27.

How much money does Gamida Cell make?

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $75.18 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does Gamida Cell have?

The company employs 166 workers across the globe.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 12/9/2022 by MarketBeat.com Staff